Combination between 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1H)-yl]propoxy}benzamide and an NMDA receptor antagonist, and pharmaceutical compositions containing it

摘要

The present invention relates to a new combination between 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1H)-yl]propoxy}benzamide of formula (I):or an addition salt thereof with a pharmaceutically acceptable acid or base, and an NMDA (N-methyl-D-aspartate) glutamatergic receptor antagonist, especially memantine, for obtaining pharmaceutical compositions for use in the treatment of cognitive disturbances associated with cerebral ageing and with neurodegenerative diseases.For treatment are mainly intended cognitive disturbances associated with Alzheimer's disease.The effects of NMDA glutamatergic receptor antagonist are potentiated by those of 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1H)-yl]propoxy}benzamide or addition salts thereof with a pharmaceutically acceptable acid or base. Co-administration of these compounds makes it possible to lower the therapeutic doses of memantine and to improve the cognitive performances of patients without increasing the adverse effects of NMDA receptor antagonist.